| Literature DB >> 33490037 |
Cecilia Yamil Chain1, María Antonieta Daza Millone1, José Sebastián Cisneros1, Eduardo Alejandro Ramirez1, María Elena Vela1.
Abstract
The development of drug carriers based in lipid nanoparticles (LNPs) aims toward the synthesis of non-toxic multifunctional nanovehicles that can bypass the immune system and allow specific site targeting, controlled release and complete degradation of the carrier components. Among label free techniques, Surface Plasmon Resonance (SPR) biosensing is a versatile tool to study LNPs in the field of nanotherapeutics research. SPR, widely used for the analysis of molecular interactions, is based on the immobilization of one of the interacting partners to the sensor surface, which can be easily achieved in the case of LNPs by hydrophobic attachment onto commercial lipid- capture sensor chips. In the last years SPR technology has emerged as an interesting strategy for studying molecular aspects of drug delivery that determines the efficacy of the nanotherapeutical such as LNPs' interactions with biological targets, with serum proteins and with tumor extracelullar matrix. Moreover, SPR has contributed to the obtention and characterization of LNPs, gathering information about the interplay between components of the formulations, their response to organic molecules and, more recently, the quantification and molecular characterization of exosomes. By the combination of available sensor platforms, assay quickness and straight forward platform adaptation for new carrier systems, SPR is becoming a high throughput technique for LNPs' characterization and analysis.Entities:
Keywords: Surface Plasmon Resonance; drug carriers; lipid nanoparticles; molecular target; protein corona
Year: 2021 PMID: 33490037 PMCID: PMC7817952 DOI: 10.3389/fchem.2020.605307
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221